Gretel S. Major
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gretel S. Major has a total of 159 co-authors. Here are the top co-authors by number of shared publications:
- Angus Lindsay
School of Biological Sciences, University of Canterbury, Christchurch, New Zealand
4 shared publications - Khoon S. Lim
University of Sydney
4 shared publications - Thomas Robert Cox
The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia
4 shared publications Anaiis Zaratzian
The Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, Australia
3 shared publicationsJiayi Chen
School of Biological Sciences University of Canterbury Christchurch New Zealand
3 shared publications- Paul Timpson
Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW 2010, Australia
3 shared publications
Latest Publications
- Open Access
ADSS1 is a suppressed metabolic control node in dystrophic skeletal muscle
Summary: Duchenne muscular dystrophy is initiated by dystrophin loss but is accompanied by profound metabolic remodelling. Here, we identify suppression of the muscle-enriched adenylosuccinate synthase, ADSS1, and the purine nucleotide cycle in mdx muscle. Integrated multi-omic profiling revealed a compensated purine-stress state in which nucleotide salvage and quality control were increased to preserve adenine nucleotide abundance and buffer consequential toxic/disruptive deoxy-/nucleotide production. Purine metabolism was the highest-impact joint pathway with metabolite and transcript hits in mdx muscle, and its maintenance program was directionally conserved in human ADSS1 myopathy. Interventions positioned around ADSS1 separated the outputs of this node. Ribose and dimethyl fumarate remodelled upstream or downstream stress programs, whereas only adenylosuccinic acid bypassed ADSS1 to expand the adenine nucleotide pool and remodel CoA/acetyl-CoA metabolism. All three interventions suppressed pro-adipogenic transcription without broadly correcting the lipidome. These findings identify ADSS1 as a regulated metabolic control node that couples purine retention to inflammatory and adipogenic remodelling in dystrophic muscle.
Open AccessADSS1 is a suppressed metabolic control node in dystrophic skeletal muscle
Summary: Duchenne muscular dystrophy is initiated by dystrophin loss but is accompanied by profound metabolic remodelling. Here, we identify suppression of the muscle-enriched adenylosuccinate synthase, ADSS1, and the purine nucleotide cycle in mdx muscle. Integrated multi-omic profiling revealed a compensated purine-stress state in which nucleotide salvage and quality control were increased to preserve adenine nucleotide abundance and buffer consequential toxic/disruptive deoxy-/nucleotide production. Purine metabolism was the highest-impact joint pathway with metabolite and transcript hits in mdx muscle, and its maintenance program was directionally conserved in human ADSS1 myopathy. Interventions positioned around ADSS1 separated the outputs of this node. Ribose and dimethyl fumarate remodelled upstream or downstream stress programs, whereas only adenylosuccinic acid bypassed ADSS1 to expand the adenine nucleotide pool and remodel CoA/acetyl-CoA metabolism. All three interventions suppressed pro-adipogenic transcription without broadly correcting the lipidome. These findings identify ADSS1 as a regulated metabolic control node that couples purine retention to inflammatory and adipogenic remodelling in dystrophic muscle.
- Open Access
- 28 May 2026
- Published by Wiley in The Journal of Physiology
- Vol. 604 (14) , 5984-6008
Regimen‐dependent glucocorticoid effects improve muscle performance without altering CNS physiology in mdx mice
Duchenne muscular dystrophy (DMD) is a multisystem disorder affecting striated muscle, metabolism and the central nervous system (CNS). Although glucocorticoids remain the standard therapy, muscle‐centric evaluations typically fail to capture how dosing regimen and compound selection affect CNS and metabolic phenotypes. Here, we compared daily and weekly dosing of prednisolone and vamorolone in juvenile mdx mice over 6 weeks to determine how these variables influence multisystem outcomes. Multiorgan efficacy and adverse effects were quantified across behavioural, endocrine, metabolic, cardiovascular and muscle domains using behavioural assays, in vivo and functional muscle testing, haemodynamic evaluation and histopathology. Daily glucocorticoid dosing failed to improve muscle function or strength, whereas weekly vamorolone produced the most robust improvements in functional and in vivo muscle strength. Daily prednisolone reduced circulating creatine kinase levels, but this biochemical change did not translate into enhanced muscle function outcomes. Daily regimens also induced severe adrenal cortical atrophy, yet these endocrine alterations were dissociated from CNS stress and anxiety responses, which remained unchanged by treatment. In addition, daily dosing caused pronounced systemic metabolic consequences, whereas weekly regimens substantially attenuated these effects, identifying dosing frequency as a key determinant of safety. Together, these findings demonstrate that glucocorticoid regimen selection fundamentally reshapes the efficacy versus adverse effect profile and underscores the value of integrated multiorgan evaluation in DMD. This work highlights the need to expand therapeutic assessments beyond muscle pathology and raises new questions about how glucocorticoid signalling differentially engages peripheral and central physiological systems. image Key points: Duchenne muscular dystrophy affects multiple physiological systems, yet current glucocorticoid assessments rarely capture the CNS and metabolic effects of dosing regimens. Weekly vamorolone dosing improved muscle strength in mdx mice, while daily prednisolone failed to improve performance despite lowering plasma creatine kinase. Stress‐ and anxiety‐related behaviours remained unchanged, despite adrenal atrophy revealing a disconnect between peripheral endocrine disruption and CNS phenotypes. Daily glucocorticoid regimens triggered endocrine and metabolic side effects, whereas weekly dosing reduced these effects. Prednisolone and vamorolone produced broadly similar systemic side‐effect profiles, but dosing frequency was the primary determinant of their severity.
- 28 May 2026
- Published by Wiley in The Journal of Physiology
- Vol. 604 (14) , 5984-6008
Open AccessRegimen‐dependent glucocorticoid effects improve muscle performance without altering CNS physiology in mdx mice
Duchenne muscular dystrophy (DMD) is a multisystem disorder affecting striated muscle, metabolism and the central nervous system (CNS). Although glucocorticoids remain the standard therapy, muscle‐centric evaluations typically fail to capture how dosing regimen and compound selection affect CNS and metabolic phenotypes. Here, we compared daily and weekly dosing of prednisolone and vamorolone in juvenile mdx mice over 6 weeks to determine how these variables influence multisystem outcomes. Multiorgan efficacy and adverse effects were quantified across behavioural, endocrine, metabolic, cardiovascular and muscle domains using behavioural assays, in vivo and functional muscle testing, haemodynamic evaluation and histopathology. Daily glucocorticoid dosing failed to improve muscle function or strength, whereas weekly vamorolone produced the most robust improvements in functional and in vivo muscle strength. Daily prednisolone reduced circulating creatine kinase levels, but this biochemical change did not translate into enhanced muscle function outcomes. Daily regimens also induced severe adrenal cortical atrophy, yet these endocrine alterations were dissociated from CNS stress and anxiety responses, which remained unchanged by treatment. In addition, daily dosing caused pronounced systemic metabolic consequences, whereas weekly regimens substantially attenuated these effects, identifying dosing frequency as a key determinant of safety. Together, these findings demonstrate that glucocorticoid regimen selection fundamentally reshapes the efficacy versus adverse effect profile and underscores the value of integrated multiorgan evaluation in DMD. This work highlights the need to expand therapeutic assessments beyond muscle pathology and raises new questions about how glucocorticoid signalling differentially engages peripheral and central physiological systems. image Key points: Duchenne muscular dystrophy affects multiple physiological systems, yet current glucocorticoid assessments rarely capture the CNS and metabolic effects of dosing regimens. Weekly vamorolone dosing improved muscle strength in mdx mice, while daily prednisolone failed to improve performance despite lowering plasma creatine kinase. Stress‐ and anxiety‐related behaviours remained unchanged, despite adrenal atrophy revealing a disconnect between peripheral endocrine disruption and CNS phenotypes. Daily glucocorticoid regimens triggered endocrine and metabolic side effects, whereas weekly dosing reduced these effects. Prednisolone and vamorolone produced broadly similar systemic side‐effect profiles, but dosing frequency was the primary determinant of their severity.
- Open Access
Regimen-dependent glucocorticoid effects improve muscle performance without altering CNS physiology in mdx mice
Duchenne muscular dystrophy (DMD) is a multisystem disorder affecting striated muscle, metabolism, and the central nervous system (CNS). Although glucocorticoids remain the standard therapy, muscle-centric evaluations typically fail to capture how dosing regimen and compound selection affect CNS and metabolic phenotypes. Here, we compared daily and weekly dosing of prednisolone and vamorolone in juvenile mdx mice over six weeks to determine how these variables influence multisystem outcomes. Multiorgan efficacy and adverse effects were quantified across behavioural, endocrine, metabolic, cardiovascular, and muscle domains using behavioural assays, in vivo and functional muscle testing, haemodynamic evaluation and histopathology. Daily glucocorticoid dosing failed to improve muscle function or strength, whereas weekly vamorolone produced the most robust improvements in functional and in vivo muscle strength. Daily prednisolone reduced circulating creatine kinase levels, but this biochemical change did not translate into enhanced muscle function outcomes. Daily regimens also induced severe adrenal cortical atrophy, yet these endocrine alterations were dissociated from CNS stress and anxiety responses, which remained unchanged by treatment. In addition, daily dosing caused pronounced systemic metabolic consequences, whereas weekly regimens substantially attenuated these effects, identifying dosing frequency as a key determinant of safety. Together, these findings demonstrate that glucocorticoid regimen selection fundamentally reshapes the efficacy–adverse effect profile and underscores the value of integrated multiorgan evaluation in DMD. This work highlights the need to expand therapeutic assessments beyond muscle pathology and raises new questions about how glucocorticoid signalling differentially engages peripheral and central physiological systems.
Open AccessRegimen-dependent glucocorticoid effects improve muscle performance without altering CNS physiology in mdx mice
Duchenne muscular dystrophy (DMD) is a multisystem disorder affecting striated muscle, metabolism, and the central nervous system (CNS). Although glucocorticoids remain the standard therapy, muscle-centric evaluations typically fail to capture how dosing regimen and compound selection affect CNS and metabolic phenotypes. Here, we compared daily and weekly dosing of prednisolone and vamorolone in juvenile mdx mice over six weeks to determine how these variables influence multisystem outcomes. Multiorgan efficacy and adverse effects were quantified across behavioural, endocrine, metabolic, cardiovascular, and muscle domains using behavioural assays, in vivo and functional muscle testing, haemodynamic evaluation and histopathology. Daily glucocorticoid dosing failed to improve muscle function or strength, whereas weekly vamorolone produced the most robust improvements in functional and in vivo muscle strength. Daily prednisolone reduced circulating creatine kinase levels, but this biochemical change did not translate into enhanced muscle function outcomes. Daily regimens also induced severe adrenal cortical atrophy, yet these endocrine alterations were dissociated from CNS stress and anxiety responses, which remained unchanged by treatment. In addition, daily dosing caused pronounced systemic metabolic consequences, whereas weekly regimens substantially attenuated these effects, identifying dosing frequency as a key determinant of safety. Together, these findings demonstrate that glucocorticoid regimen selection fundamentally reshapes the efficacy–adverse effect profile and underscores the value of integrated multiorgan evaluation in DMD. This work highlights the need to expand therapeutic assessments beyond muscle pathology and raises new questions about how glucocorticoid signalling differentially engages peripheral and central physiological systems.
- 1 January 2026
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 140 (1) , 39-56
Dystrophin deficiency stiffens skeletal muscle and impairs elasticity: an in vivo rheological examination
Myomechanical profiling was developed using cyclic rheometry to assess the in vivo viscoelastic properties of mouse skeletal muscle—the in vivo environment is maintained alongside high measurement sensitivity and spatial resolution, and the ability to apply deformation transverse to fiber orientation. Myomechanical profiling was trialed in dystrophin-positive and dystrophin-negative (model of Duchenne muscular dystrophy) skeletal muscle, and showed that the loss of the biomechanical protein dystrophin increased stiffness and impaired elasticity after compressive and rotational shear deformation.
- 1 January 2026
- Published by American Physiological Society in Journal of Applied Physiology
- Vol. 140 (1) , 39-56
Dystrophin deficiency stiffens skeletal muscle and impairs elasticity: an in vivo rheological examination
Myomechanical profiling was developed using cyclic rheometry to assess the in vivo viscoelastic properties of mouse skeletal muscle—the in vivo environment is maintained alongside high measurement sensitivity and spatial resolution, and the ability to apply deformation transverse to fiber orientation. Myomechanical profiling was trialed in dystrophin-positive and dystrophin-negative (model of Duchenne muscular dystrophy) skeletal muscle, and showed that the loss of the biomechanical protein dystrophin increased stiffness and impaired elasticity after compressive and rotational shear deformation.
- Open Access
- 7 March 2025
- Published by CSIRO Publishing in Australian Journal of Zoology
- Vol. 73 (2)
Population differentiation in the white-fronted chat (Epthianura albifrons) at a continental scale: implications for dispersal, biogeography and conservation
The capacity for dispersal is an important determinant of a species’ resilience to decline from the serial extinction of local populations. Dispersal of animals can be difficult to measure directly but population genetics provides a powerful tool for identifying dispersal limits. This study used microsatellite markers to investigate population structuring of the white-fronted chat (Epthianura albifrons) across its geographic range. Because the species is threatened in the north-eastern part of its range, the primary aim was to identify barriers limiting dispersal. Isolation by distance was not apparent across the 3000 km mainland range but populations on three oceanic islands, and two mainland sites surrounded by urbanisation, were genetically distinct from each other and the other mainland sites. The small populations that were surrounded by urbanised land had significantly lower genetic diversity (allelic diversity and heterozygosity) than the other mainland populations, with the oceanic island populations showing intermediate levels of diversity. These results suggest that although being a partially nomadic species, which facilitates its dispersal over continuous habitat, the species does not have the flight capacity of some other small passerines and is sensitive to habitat discontinuity. Populations inhabiting small areas of coastal saltmarsh in areas with large human populations are likely to face increasing threat levels.
- 7 March 2025
- Published by CSIRO Publishing in Australian Journal of Zoology
- Vol. 73 (2)
Open AccessPopulation differentiation in the white-fronted chat (Epthianura albifrons) at a continental scale: implications for dispersal, biogeography and conservation
The capacity for dispersal is an important determinant of a species’ resilience to decline from the serial extinction of local populations. Dispersal of animals can be difficult to measure directly but population genetics provides a powerful tool for identifying dispersal limits. This study used microsatellite markers to investigate population structuring of the white-fronted chat (Epthianura albifrons) across its geographic range. Because the species is threatened in the north-eastern part of its range, the primary aim was to identify barriers limiting dispersal. Isolation by distance was not apparent across the 3000 km mainland range but populations on three oceanic islands, and two mainland sites surrounded by urbanisation, were genetically distinct from each other and the other mainland sites. The small populations that were surrounded by urbanised land had significantly lower genetic diversity (allelic diversity and heterozygosity) than the other mainland populations, with the oceanic island populations showing intermediate levels of diversity. These results suggest that although being a partially nomadic species, which facilitates its dispersal over continuous habitat, the species does not have the flight capacity of some other small passerines and is sensitive to habitat discontinuity. Populations inhabiting small areas of coastal saltmarsh in areas with large human populations are likely to face increasing threat levels.
- Open Access
- 16 February 2024
- Published by Elsevier in Materials Today Bio
- Vol. 25, 101004
Programming temporal stiffness cues within extracellular matrix hydrogels for modelling cancer niches
- 16 February 2024
- Published by Elsevier in Materials Today Bio
- Vol. 25, 101004
Open AccessProgramming temporal stiffness cues within extracellular matrix hydrogels for modelling cancer niches
- 5 February 2024
- Published by Elsevier in Trends in Biotechnology
- Vol. 42 (7) , 859-876
Mapping the microcarrier design pathway to modernise clinical mesenchymal stromal cell expansion
- 5 February 2024
- Published by Elsevier in Trends in Biotechnology
- Vol. 42 (7) , 859-876
Mapping the microcarrier design pathway to modernise clinical mesenchymal stromal cell expansion
- Top Cited PapersOpen Access
- 28 August 2023
- Published by Springer Nature in Nature Cancer
- Vol. 4 (9) , 1326-1344
A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer
The lysyl oxidase family represents a promising target in stromal targeting of solid tumors due to the importance of this family in crosslinking and stabilizing fibrillar collagens and its known role in tumor desmoplasia. Using small-molecule drug-design approaches, we generated and validated PXS-5505, a first-in-class highly selective and potent pan-lysyl oxidase inhibitor. We demonstrate in vitro and in vivo that pan-lysyl oxidase inhibition decreases chemotherapy-induced pancreatic tumor desmoplasia and stiffness, reduces cancer cell invasion and metastasis, improves tumor perfusion and enhances the efficacy of chemotherapy in the autochthonous genetically engineered KPC model, while also demonstrating antifibrotic effects in human patient-derived xenograft models of pancreatic cancer. PXS-5505 is orally bioavailable, safe and effective at inhibiting lysyl oxidase activity in tissues. Our findings present the rationale for progression of a pan-lysyl oxidase inhibitor aimed at eliciting a reduction in stromal matrix to potentiate chemotherapy in pancreatic ductal adenocarcinoma.
- 28 August 2023
- Published by Springer Nature in Nature Cancer
- Vol. 4 (9) , 1326-1344
Top Cited PapersOpen AccessA first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer
The lysyl oxidase family represents a promising target in stromal targeting of solid tumors due to the importance of this family in crosslinking and stabilizing fibrillar collagens and its known role in tumor desmoplasia. Using small-molecule drug-design approaches, we generated and validated PXS-5505, a first-in-class highly selective and potent pan-lysyl oxidase inhibitor. We demonstrate in vitro and in vivo that pan-lysyl oxidase inhibition decreases chemotherapy-induced pancreatic tumor desmoplasia and stiffness, reduces cancer cell invasion and metastasis, improves tumor perfusion and enhances the efficacy of chemotherapy in the autochthonous genetically engineered KPC model, while also demonstrating antifibrotic effects in human patient-derived xenograft models of pancreatic cancer. PXS-5505 is orally bioavailable, safe and effective at inhibiting lysyl oxidase activity in tissues. Our findings present the rationale for progression of a pan-lysyl oxidase inhibitor aimed at eliciting a reduction in stromal matrix to potentiate chemotherapy in pancreatic ductal adenocarcinoma.
- Open Access
- 25 December 2022
- Published by Wiley in Advanced Healthcare Materials
- Vol. 12 (14) , e2201581
Biofabrication of Modular Spheroids as Tumor‐Scale Microenvironments for Drug Screening
To streamline the drug discovery pipeline, there is a pressing need for preclinical models which replicate the complexity and scale of native tumors. While there have been advancements in the formation of microscale tumor units, these models are cell‐line dependent, time‐consuming and have not improved clinical trial success rates. In this study, two methods for generating 3D tumor microenvironments are compared, rapidly fabricated hydrogel microspheres and traditional cell‐dense spheroids. These modules are then bioassembled into 3D printed thermoplastic scaffolds, using an automated biofabrication process, to form tumor‐scale models. Modules are formed with SKOV3 and HFF cells as monocultures and cocultures, and the fabrication efficiency, cell architecture, and drug response profiles are characterized, both as single modules and as multimodular constructs. Cell‐encapsulated Gel‐MA microspheres are fabricated with high‐reproducibility and dimensions necessary for automated tumor‐scale bioassembly regardless of cell type, however, only cocultured spheroids form compact modules suitable for bioassembly. Chemosensitivity assays demonstrate the reduced potency of doxorubicin in coculture bioassembled constructs and a ≈five‐fold increase in drug resistance of cocultured cells in 3D modules compared with 2D monolayers. This bioassembly system is efficient and tailorable so that a variety of relevant‐sized tumor constructs could be developed to study tumorigenesis and modernize drug discovery.
- 25 December 2022
- Published by Wiley in Advanced Healthcare Materials
- Vol. 12 (14) , e2201581
Open AccessBiofabrication of Modular Spheroids as Tumor‐Scale Microenvironments for Drug Screening
To streamline the drug discovery pipeline, there is a pressing need for preclinical models which replicate the complexity and scale of native tumors. While there have been advancements in the formation of microscale tumor units, these models are cell‐line dependent, time‐consuming and have not improved clinical trial success rates. In this study, two methods for generating 3D tumor microenvironments are compared, rapidly fabricated hydrogel microspheres and traditional cell‐dense spheroids. These modules are then bioassembled into 3D printed thermoplastic scaffolds, using an automated biofabrication process, to form tumor‐scale models. Modules are formed with SKOV3 and HFF cells as monocultures and cocultures, and the fabrication efficiency, cell architecture, and drug response profiles are characterized, both as single modules and as multimodular constructs. Cell‐encapsulated Gel‐MA microspheres are fabricated with high‐reproducibility and dimensions necessary for automated tumor‐scale bioassembly regardless of cell type, however, only cocultured spheroids form compact modules suitable for bioassembly. Chemosensitivity assays demonstrate the reduced potency of doxorubicin in coculture bioassembled constructs and a ≈five‐fold increase in drug resistance of cocultured cells in 3D modules compared with 2D monolayers. This bioassembly system is efficient and tailorable so that a variety of relevant‐sized tumor constructs could be developed to study tumorigenesis and modernize drug discovery.
- 28 October 2021
- Published by Wiley in Advanced Healthcare Materials
- Vol. 11 (2) , 2101873
Development and Characterization of Gelatin‐Norbornene Bioink to Understand the Interplay between Physical Architecture and Micro‐Capillary Formation in Biofabricated Vascularized Constructs
The principle challenge for engineering viable, cell‐laden hydrogel constructs of clinically‐relevant size, is rapid vascularization, in order to moderate the finite capacity of passive nutrient diffusion. A multiscale vascular approach, with large open channels and bulk microcapillaries may be an admissible approach to accelerate this process, promoting overall pre‐vascularization for long‐term viability of constructs. However, the limited availability of bioinks that possess suitable characteristics that support both fabrication of complex architectures and formation of microcapillaries, remains a barrier to advancement in this space. In this study, gelatin‐norbornene (Gel‐NOR) is investigated as a vascular bioink with tailorable physico‐mechanical properties, which promoted the self‐assembly of human stromal and endothelial cells into microcapillaries, as well as being compatible with extrusion and lithography‐based biofabrication modalities. Gel‐NOR constructs containing self‐assembled microcapillaries are successfully biofabricated with varying physical architecture (fiber diameter, spacing, and orientation). Both channel sizes and cell types affect the overall structural changes of the printed constructs, where cross‐signaling between both human stromal and endothelial cells may be responsible for the reduction in open channel lumen observed over time. Overall, this work highlights an exciting three‐way interplay between bioink formulation, construct design, and cell‐mediated response that can be exploited towards engineering vascular tissues.
- 28 October 2021
- Published by Wiley in Advanced Healthcare Materials
- Vol. 11 (2) , 2101873
Development and Characterization of Gelatin‐Norbornene Bioink to Understand the Interplay between Physical Architecture and Micro‐Capillary Formation in Biofabricated Vascularized Constructs
The principle challenge for engineering viable, cell‐laden hydrogel constructs of clinically‐relevant size, is rapid vascularization, in order to moderate the finite capacity of passive nutrient diffusion. A multiscale vascular approach, with large open channels and bulk microcapillaries may be an admissible approach to accelerate this process, promoting overall pre‐vascularization for long‐term viability of constructs. However, the limited availability of bioinks that possess suitable characteristics that support both fabrication of complex architectures and formation of microcapillaries, remains a barrier to advancement in this space. In this study, gelatin‐norbornene (Gel‐NOR) is investigated as a vascular bioink with tailorable physico‐mechanical properties, which promoted the self‐assembly of human stromal and endothelial cells into microcapillaries, as well as being compatible with extrusion and lithography‐based biofabrication modalities. Gel‐NOR constructs containing self‐assembled microcapillaries are successfully biofabricated with varying physical architecture (fiber diameter, spacing, and orientation). Both channel sizes and cell types affect the overall structural changes of the printed constructs, where cross‐signaling between both human stromal and endothelial cells may be responsible for the reduction in open channel lumen observed over time. Overall, this work highlights an exciting three‐way interplay between bioink formulation, construct design, and cell‐mediated response that can be exploited towards engineering vascular tissues.